Palimpsest Bio Corp. — SEC Form D Filing

Palimpsest Bio Corp. filed an SEC Form D on October 30, 2026, reporting $172K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 30, 2026
Amount reported
$172K
Round stage
Pre-seed phase given the preliminary $172,000 capital raised via a SAFE instrument to initiate foundational drug discovery operations.
Industry
Biotechnology
Website
https://palimpsest.bio

What the company does

Securities: Simple Agreement for Future Equity (SAFE). Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional drug discovery pipelines suffer from low clinical success rates due to inadequate biological target validation and complex data processing limitations.

Solution

Palimpsest Bio develops proprietary biological discovery technologies to identify and validate novel therapeutic targets for complex diseases.

Why now

Advances in high-throughput biological screening and data analytics now enable early-stage biotechnology platforms to decode complex cellular mechanisms with minimal initial capital.

Verdict

At $172,000, this was an exploratory angel check rather than a capitalized institutional round. This cleared because early backers bought cheap optionality on an early molecular control hypothesis, not because Palimpsest demonstrated a proprietary wet-lab moat or verified pharma demand. Investors implicitly bet that a minimal proof-of-concept could be achieved on personal or incubator balance sheets. However, the micro-raise severely limits durability, leaving the company instantly exposed to dilution and execution stalls in a therapeutic category where venture-backed peers deploy tens of millions to generate baseline pre-clinical validation.

Source: SEC EDGAR Form D filing